Table 2 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

Alexander Muik; Elena Garralda; Işıl Altıntaş; Friederike Gieseke; Ravit Geva; Eytan Ben‐Ami; Corinne Maurice‐Dror; Emiliano Calvo; Patricia LoRusso; Guzmán Alonso; María E. Rodriguez-Ruiz; Kristina B. Schoedel; Jordan M. Blum; Bianca Sänger; Theodora W. Salcedo; Saskia M. Burm; Eliana Stanganello; Dennis Verzijl; Fulvia Vascotto; Angelica Sette; Juliane Quinkhardt; Theo S. Plantinga; Aras Toker; Edward N. van den Brink; Mark Fereshteh; Mustafa Diken; David Satijn; Sebastian Kreiter; Esther C.W. Breij; Gaurav Bajaj; Eleni Lagkadinou; Kate Sasser; Özlem Türeci; Ulf Forssmann; Tahamtan Ahmadi; Uğur Şahin; Maria Jure‐Kunkel; Ignacio Melero

doi:10.1158/2159-8290.30834188

Abstract

<p>Treatment-related AEs reported in >2 patients treated with GEN1046 (<i>n</i> = 61)</p>

Related Publications

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

Seung Tae Kim , Răzvan Cristescu , Adam J. Bass +20 more

Clinical studies support the efficacy of programmed cell death 1 (PD-1) targeted therapy in a subset of patients with metastatic gastric cancer (mGC). With the goal of identifyi...

2018 Nature Medicine 1624 citations

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

Jun Gong , Alex Chehrazi‐Raffle , Srikanth Reddi +1 more

Early preclinical evidence provided the rationale for programmed cell death 1 (PD-1) and programmed death ligand 1 (PD-L1) blockade as a potential form of cancer immunotherapy g...

2018 Journal for ImmunoTherapy of Cancer 1280 citations

Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC).

Daniel C. Cho , Jeffrey A. Sosman , Mario Sznol +11 more

4505 Background: Human RCC expresses PD-L1 and has been shown to respond to immune-based therapy. MPDL3280A, a human monoclonal antibody containing an engineered Fc-domain desig...

2013 Journal of Clinical Oncology 97 citations

Restoring Immune Function of Tumor-Specific CD4+ T Cells during Recurrence of Melanoma

Stephen R. Goding , Kyle Wilson , Ying Xie +7 more

Abstract Recurrent solid malignancies are often refractory to standard therapies. Although adoptive T cell transfer may benefit select individuals, the majority of patients succ...

2013 The Journal of Immunology 204 citations

Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer

Charlotte Roach , Nancy Zhang , Ellie Corigliano +7 more

A companion diagnostic assay was codeveloped by Dako for pembrolizumab non–small-cell lung cancer clinical trials to detect PD-L1 expression by immunohistochemistry (IHC). This ...

2016 Applied immunohistochemistry & molecu... 346 citations

Publication Info

Year: 2025
Type: article
Citations: 0
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Table 2 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

OpenAlex

Cite This

APA Style

                            
                                    Alexander Muik, 
                                
                                    Elena Garralda, 
                                
                                    Işıl Altıntaş
                                
                                et al.
                            
                            (2025). 
                            Table 2 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors. 
                            
                            .
                            https://doi.org/10.1158/2159-8290.30834188

Identifiers

DOI: 10.1158/2159-8290.30834188